AlzeCure Pharma
30.8.2021 14:11:55 CEST | ACCESS Newswire | Press release
STOCKHOLM, SE / ACCESSWIRE / August 30, 2021 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6)
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced that the company has received approval from the regulatory authorities in Sweden to begin the next clinical phase I study (multiple ascending dose, MAD) with the candidate drug ACD856 focused on Alzheimer's disease.
The MAD Phase I study is AlzeCure's third clinical study with ACD856, the lead candidate drug within the company's NeuroRestore platform. ACD856 is being developed as a symptom-relieving treatment for disease states where the cognitive ability is impaired, such as in Alzheimer's disease. The primary study goal is to evaluate ACD856's tolerability and safety after repeated dosing, as well as to examine early signals on brain activity.
The substances in the NeuroRestore platform stimulate several important signaling pathways in the brain, which, among other things, leads to improved cognition. Preclinical studies have shown that AlzeCure's candidate drugs strengthen the communication between nerve cells and improve cognitive ability including memory functions.
"I'm very pleased that we have all regulatory approvals in place to be able to start the next study with ACD856. This means we will be able to start the MAD study during the fall, which is in line with our previously communicated goals," said Johan Sandin, CSO at AlzeCure Pharma.
"This is a statement of strength that shows that AlzeCure continues to deliver according to plan," said Martin Jönsson, CEO of AlzeCure Pharma AB. "Diseases with cognitive disorders, and especially Alzheimer's disease, are areas with high need of new, more effective treatments and I am very much looking forward to the continued development of this important candidate drug".AlzeCure Pharma will give a strategic update on Alzheimer's disease and the NeuroRestore platform on September 1 at 9 a.m. CET at Redeye. Watch the livestream via: https://www.redeye.se/events/816325/strategy-update-alzecure-pharma-2.
For more information, please contact
Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com
About AlzeCure Pharma AB (publ)
AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.
NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development to an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies. FNCA Sweden AB, +46(0)8 528 00 399 info@fnca.se , is the company's Certified Adviser., For more information, please visit www.alzecurepharma.se .
About NeuroRestore
NeuroRestore is a platform of symptom-relieving drug candidates for disease states in which cognitive ability is impaired, e.g. Alzheimer's Disease, sleep apnea, traumatic brain injury and Parkinson's disease. NeuroRestore stimulates several important signaling pathways in the brain, which among other things leads to improved cognition. In preclinical studies with NeuroRestore we have been able to show that our drug candidates enhance communication between the nerve cells and improve cognitive ability. NeuroRestore stimulates specific signaling pathways in the central nervous system known as neurotrophins, the most well-known being NGF (Nerve Growth Factor) and BDNF (Brain Derived Neurotrophic Factor). The levels of NGF and BDNF are disturbed in several disease states and the signaling is reduced. The impaired function impairs communication between the synapses, i.e. the contact surfaces of the nerve endings, as well as reducing the possibility of survival for the nerve cells, which gives rise to the cognitive impairments. Neurotrophins play a crucial role for the function of nerve cells, and a disturbed function of BDNF has a strong genetic link to impaired cognitive ability in several different diseases, such as Alzheimer's, Parkinson's disease, traumatic brain injury and sleep disorders. There is also a link between BDNF signaling and depression, something that has been further strengthened in recent years.
About Alzheimer's disease
Alzheimer's disease is the most common form of dementia, affecting approximately 45 million people worldwide. Alzheimer's disease is a lethal disorder that also has a large impact on both relatives and the society. Today, preventive and disease modifying treatments are missing. The main risk factors to develop Alzheimer's are age and genetic causes. Even though the disease can start as early as between 40 and 65 years of age, it is most common after 65 years. Significant investments in Alzheimer research are being made because of the significant unmet medical need and the large cost of this disease for healthcare and society. The total global costs for dementia related diseases is estimated to about 1,000 billion USD globally in 2018. Given the lack of both effective symptomatic treatments and disease modifying treatments, the need for new effective therapies is acute. The few approved drugs on the market today have only a limited symptomatic effect and can produce dose limiting side effects. A disease modifying treatment for Alzheimer's disease is estimated to reach more than $10 billion in annual sales. In Sweden, approximately 100,000 people suffer from Alzheimer's disease with a healthcare cost of about SEK 63 billion yearly, which is more than for cancer and cardiovascular diseases combined.
Image Attachments
Martin Jönsson CEO AlzeCure Pharma
Attachments
AlzeCure's Alzheimer's project receives approval to start next clinical phase I study with ACD856
SOURCE: AlzeCure Pharma
View source version on accesswire.com:
https://www.accesswire.com/661943/AlzeCures-Alzheimers-Project-Receives-Approval-to-start-Next-Clinical-Phase-I-Study-with-ACD856
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Chervon Promotes Soobia Haroon to Vice President, Human Resources - NA2.11.2026 15:00:00 CET | Press release
NAPERVILLE, IL / ACCESS Newswire / November 2, 2026 / Chervon promotes Soobia Haroon to Vice President, Human Resources - NA, effective November 2, 2026, reporting to Joe Galli, CEO. Over the past two years, Haroon has been a key member of the Chervon Senior Executive Team, driving talent acquisition, organizational development, and transformation. She has provided strategic leadership across all HR functions while strengthening corporate HR strategy, governance, and processes to support the company's objectives and continued growth. Before joining Chervon, Soobia progressed through a series of human resources positions at several multinational companies. Her HR experience is strong in supporting many functional areas, including supply chain, distribution, manufacturing, IT, engineering, product management, marketing, and finance. "Soobia has been instrumental in our aggressive talent acquisition initiative since I joined Chervon," said Joe Galli. "Her extensive HR experience, her sens
Chervon Names Thomas Scherer Vice President of Organizational Development - Sales, End User Marketing, and Service2.11.2026 15:00:00 CET | Press release
NAPERVILLE, IL / ACCESS Newswire / November 2, 2026 / Chervon names Thomas Scherer Vice President of Organizational Development - Sales, End User Marketing, and Service, effective November 2, 2026, reporting to Matt DeFeo, SVP, Sales, Training, and Recruiting. Scherer brings to Chervon extensive organizational development experience supporting the build-out of large-scale sales teams and end user marketing teams. He is highly experienced in managing employment law, compliance, employee relations, compensation, workforce analytics, training, recruiting, and career development. His world class organizational development skills will be invaluable as the company develops the very best sales, store coverage, end user marketing, and after-sales service teams. Most recently, Tom was Vice President of Human Resources for TTI/Milwaukee where he was responsible for HR and organizational development for a 2000+ person field sales team. Previously, Scherer advanced through a series of HR, training
Chervon Names Jody Grimsley Senior National Account Manager2.11.2026 15:00:00 CET | Press release
NAPERVILLE, IL / ACCESS Newswire / November 2, 2026 / Jody Grimsley joins Chervon as Senior National Account Manager, effective November 2, 2026, reporting to Jeff Campbell, SVP of Industrial Commercial Sales. In his new role, Grimsley will focus on developing key strategic relationships with commercial landscape dealers, driving growth of the EGO Commercial OPE range. Jody brings 17+ years of commercial sales experience at TTI/Milwaukee. His outstanding sales growth performance included building significant businesses in the Transportation Channel and Hardware Channel. Earlier in his career, he excelled through sales roles of increasing complexity and as a Regional Sales Manager in the Industrial Channel. "Jody brings a strong track record of developing strategic relationships, driving outstanding sales growth and building successful sales organizations," said Jeff Campbell. "His extensive key account experience and his customer-centric approach will be invaluable as we build our busi
Hydrosat Announces Nyktòs Program to Provide Tactical ISR for Sovereign Customers from New Facility in Europe2.11.2026 12:00:00 CET | Press release
LUXEMBOURG, LU / ACCESS Newswire / November 2, 2026 / Hydrosat, the leading provider of thermal infrared satellite solutions, announced today its high-resolution mid-wave infrared (MWIR) program named Nyktòs. Nyktòs will deliver high-resolution thermal imaging for tactical ISR. The day-and-night imaging capability can be tasked by customers and is complementary to the wide-area monitoring provided by Hydrosat's Osiris constellation. The development of the new capability will be supported by Hydrosat's expanded technology and manufacturing footprint in Europe and is intended for sovereign mission applications for NATO and allied customers. As part of the expansion, Hydrosat will open additional facilities, grow its network of European supply chain partners and advance the development of high-resolution mid-wave infrared technology in the region. Together, these investments will strengthen the company's ability to support sovereign government and allied missions across national security,
Aer Lingus and MTech Mobility Launch Live Ground Operations Technology Programme Across Three Irish Airports2.11.2026 11:00:00 CET | Press release
WEXFORD, IRELAND / ACCESS Newswire / November 2, 2026 / Aer Lingus and MTech Mobility have launched a new mobility-based hands-free scanning and communications solution across below-the-wing ground operations at Dublin, Cork, and Shannon airports. The programme is fully live at all three locations. The programme was built around three operational goals Aer Lingus set out to achieve: faster, more accurate baggage scanning that keeps handlers' hands free to move luggage; a single device that works as both a scanning tool and a real-time communications channel for ground teams; and personal device ownership for staff, ending the long-standing problem of shared equipment going missing between shifts. "Our ground teams work in one of the most demanding environments in the business. Our focus at Aer Lingus is operational resilience, efficiency, and consistency, and we needed a partner who understood that before they proposed a solution - one who would own the programme from day one, not just
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom